Skip to main content
Premium Trial:

Request an Annual Quote

Artemis to Provide Biovitrum with RNAi-modified Transgenic Mice

NEW YORK, July 7 (GenomeWeb News) - Artemis Pharmaceuticals will provide Biovitrum with RNAi-modified transgenic mice, the companies said today.

 

Under the agreement, Cologne, Germany-based Artemis will create shRNAi knock-down transgenic mice for Biovitrum of Stockholm, Sweden.

 

Biovitrum will use these mice, in which the expression of certain proteins will be down-regulated, in its pharmaceutical research programs.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more